WO1992004464A3 - Monoclonal antibodies against tenascin - Google Patents

Monoclonal antibodies against tenascin Download PDF

Info

Publication number
WO1992004464A3
WO1992004464A3 PCT/US1991/006433 US9106433W WO9204464A3 WO 1992004464 A3 WO1992004464 A3 WO 1992004464A3 US 9106433 W US9106433 W US 9106433W WO 9204464 A3 WO9204464 A3 WO 9204464A3
Authority
WO
WIPO (PCT)
Prior art keywords
monoclonal antibodies
antibodies against
tenascin
against tenascin
melanomas
Prior art date
Application number
PCT/US1991/006433
Other languages
French (fr)
Other versions
WO1992004464A1 (en
WO1992004464A2 (en
Inventor
Meenhard Herlyn
Original Assignee
Wistar Inst
Meenhard Herlyn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wistar Inst, Meenhard Herlyn filed Critical Wistar Inst
Publication of WO1992004464A1 publication Critical patent/WO1992004464A1/en
Publication of WO1992004464A2 publication Critical patent/WO1992004464A2/en
Publication of WO1992004464A3 publication Critical patent/WO1992004464A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

This invention provides monoclonal antibodies that bind to four non-overlapping epitopes on human tenascin. This invention also provides an improved method for determining metastatic potential of melanomas, based on the discovery that metastatic melanomas secrete tenascin.
PCT/US1991/006433 1990-09-05 1991-09-05 Monoclonal antibodies against tenascin WO1992004464A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57773290A 1990-09-05 1990-09-05
US577,732 1990-09-05

Publications (3)

Publication Number Publication Date
WO1992004464A1 WO1992004464A1 (en) 1992-03-19
WO1992004464A2 WO1992004464A2 (en) 1992-03-19
WO1992004464A3 true WO1992004464A3 (en) 2004-05-13

Family

ID=

Also Published As

Publication number Publication date
WO1992004464A1 (en) 1992-03-19
AU8547291A (en) 1992-03-30

Similar Documents

Publication Publication Date Title
NL300142I2 (en) Monoclonal antibody against a cytotoxin, hybridoma cell line, which expresses that and method for the preparation of the purified cytotoxin.
IT8319234A0 (en) PROCEDURE FOR THE PRODUCTION OF HUMAN MONOCLONAL ANTIBODIES.
ES2106195T3 (en) IGG AGLYCOSILATED ANTIBODY ANTI CD3.
EP0724456A4 (en) Antibodies to cd40
EP0636029A4 (en) Antibodies specific for carcinoma-associated antigens.
AU4042195A (en) Anti-alphaV-integrin monoclonal antibody
EP0249007A3 (en) A method of screening hybridomas
WO1997046589A3 (en) Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
IT8320550A0 (en) PERAFFINITY PURIFICATION PROCEDURE IN WHICH MONOCLONAL ANTIBODIES ARE USED.
DE3854502D1 (en) AGAINST HIV-ANTIGENT SPECIFIC MONOCLONAL ANTIBODIES.
ITRM920457A0 (en) MONOCLONAL ANTIBODIES THAT RECOGNIZE AN EPITOPE OF THE HUMAN P-GLYCOPROTEIN.
AU4485493A (en) Method for generating monoclonal antibodies from rabbits
DE3885355D1 (en) Monoclonal antibodies.
ES551495A0 (en) PROCEDURE FOR OBTAINING A REACTIVE MONOCLONAL ANTIBODY WITH ESPOROZOITE OR MEROZOIT ANTIGENS FROM EIMERIA SPP.
AU567681B2 (en) Immunoassay involving monoclonal igm antibody
AU1423892A (en) Monoclonal antibodies directed towards mycobacterial antigens
WO1992004464A3 (en) Monoclonal antibodies against tenascin
NO20004251D0 (en) Humanized anti-CEA high affinity monoclonal antibodies
DE3785795D1 (en) MONOCLONAL ANTI-HUMAN CANCER ANTIBODIES.
AU3552689A (en) Monoclonal antibody for colorectal carcinoma
ITMI910491A0 (en) IMMONOTOXIN FROM ANTI-CDS MONOCLONAL ANTIBODIES
MX9202642A (en) MONOCLONAL ANTIBODIES AND ANTIGEN FOR HUMAN MELANOMA.
AU2169797A (en) Improved production of antibodies through the use of antigen antibody complexes
NO894555L (en) MONOCLONAL ANTIBODY THAT SPECIFICALLY RECOGNIZES N-GLYCOLYL TYPE GM2, HYBRIDOM THAT PRODUCES ANTIBODY AND PROCEDURE FOR PRODUCING THE HYBRIDOM.
AU2828795A (en) Monoclonal antibodies for the reduction of anti-xenogeneic immune responses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MC MG MN MW NL NO PL RO SD SE SU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/2-2/2,DRAWINGS,REPLACED BY NEW PAGES 1/2-2/2;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: CA